TīmeklisFind the latest Institutional Holdings data for Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) at Nasdaq.com. Tīmeklis2024. gada 6. apr. · NASDAQ:RANI Rani Therapeutics - RANI Price Target & Analyst Ratings $5.16 +0.09 (+1.78%) (As of 03/31/2024 12:00 AM ET) Compare Today's Range $4.80 $5.29 50-Day Range $5.07 $6.71 52-Week Range $3.65 $14.90 Volume 14,522 shs Average Volume 23,173 shs Market Capitalization $254.70 million P/E …
Rani Therapeutics Announces Repeat-Dose Topline Results from …
TīmeklisRani Therapeutics Holdings (NASDAQ: RANI) is owned by 5.97% institutional shareholders, 52.28% Rani Therapeutics Holdings insiders, and 41.76% retail investors. South Cone Investments Limited Partnership is the largest individual Rani Therapeutics Holdings shareholder, owning 13.42M shares representing 27.16% of … TīmeklisThe latest price target for Rani Therapeutics Hldgs ( NASDAQ: RANI) was reported by HC Wainwright & Co. on Thursday, March 23, 2024. The analyst firm set a price … perrottet catholic gut
RANI THERAPEUTICS HOLDINGS, INC. : RANI Stock Price
Tīmeklis2024. gada 25. marts · Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Rating) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Rani Therapeutics in a report issued on Thursday, March 23rd.HC Wainwright analyst M. Kapoor expects that the company will earn ($0.88) per share for the quarter. HC … Tīmeklis2024. gada 22. marts · Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as … Tīmeklis2024. gada 11. apr. · SAN JOSE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on ... perrottet chief of staff